All In Biotech

Drug Trial Radar · NCT04824079

Keynatinib in Treated Patients With NSCLC and Brain Metastases

Study of Keynatinib in Patients With Advanced Non-small Cell Lung Cancer With Brain Metastasis or Progression of Brain Metastasis After Treatment With EGFR Inhibitor(s)

Last checked: Nov 19, 2026Latest source record: Jan 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

16

Actual

Start

Oct 21, 2020

Primary completion

Dec 10, 2024

Study completion Dec 10, 2024

Sponsor

Lead sponsor
Medolution Ltd.Industry
Sponsor type
Industry
First posted
Apr 1, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and efficacy of Keynatinib capsules in patients with advanced non-small cell lung cancer (NSCLC) with brain metastasis or progression of brain metastasis after treatment with EGFR inhibitors. As well as, to evaluate the penetration rate of Keynatinib in the Blood-Brain Barrier (BBB) and its PK characteristics, and the relationship between exposure levels with efficacy and safety.

Conditions

  • Non-Small Cell Lung Cancer With EGFR Mutation
  • Brain Metastases

Interventions

  • KeynatinibDrug

    The recommended dose is 20 mg Keynatinib twice a day until disease progression, unacceptable toxicity death occurs or withdraw from the study, whichever occurs first.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response RateTime frame: From start of treatment to time of progression (in CNS or non-CNS disease) , intolerable toxicity, withdrawal of informed consent or death, whichever occurs first,assessed up to 2 years.

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Cancer Hospital, Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China

  • Fujian Cancer Hospital

    Fuzhou, Fujian, China

  • Henan Cancer Hospital

    Zhengzhou, Henan, China

  • Hunan Cancer Hospital

    Changsha, Hunan, China

  • Shandong Cancer Hospital

    Jinan, Shandong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.